Image of a grandfather and grandmother looking at a mother holding a baby (not actual patients) Image of a grandfather and grandmother looking at a mother holding a baby (not actual patients) mobile

What Is ELREXFIO?

How ELREXFIO works

ELREXFIO is a type of treatment called a BCMA-directed bispecific antibody, also known as a bispecific. It destroys cancer cells by binding to both CD3, a protein found on the surface of T cells, and BCMA, a protein found on the surface of B cells.

ELREXFIO binds to myeloma cells and T cells. ELREXFIO activates those T cells to help destroy myeloma cells

Tap on the labels below to learn more.

Style
elrex-works, tooltip

T cell Fighter cell

ELREXFIO binds to the CD3 protein found on the surface of T cells. This is a type of white blood cell that can act as a weapon against myeloma cells and other cells.

Myeloma cell Cancer cell

ELREXFIO is designed to bind to BCMA, a protein that is overexpressed on the surface of myeloma cells. BCMA can be found on other B cells, too.

CD3

Illustration of ELREXFIO (elranatamab-bcmm) binding to both CD3, a protein found on T-cells, and BCMA, a protein found on myeloma cells

BCMA

ELREXFIO

This dual binding process activates T cells to target and destroy myeloma cells with BCMA on their surface. It may also harm a type of normal antibody-producing cell.

Illustration of ELREXFIO (elranatamab-bcmm) binding to both CD3, a protein found on T-cells, and BCMA, a protein found on myeloma cells

T cell

CD3

ELREXFIO

BCMA

Myeloma cell

Style
mob-diag
Image of a grandfather and mother looking at a baby (not actual patients) Image of a grandfather and mother looking at a baby (not actual patients) mobile

See how people responded to ELREXFIO

See trial results